H
Helixmith Co Ltd
KOSDAQ:084990
Helixmith Co Ltd
KOSDAQ:084990
Price:
8 150
KRW
-13.39%
Market Closed
Market Cap:
₩375.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Long Hau Corp
VN:LHG
|
VN |
|
A
|
Alligo AB
STO:ALLIGO B
|
SE |
|
K
|
Koken Ltd
TSE:7963
|
JP |
|
Shanxi Meijin Energy Co Ltd
SZSE:000723
|
CN |
|
L
|
Ladun Investment Company SCJSC
SAU:9535
|
SA |
|
N
|
Nippon Denkai Ltd
TSE:5759
|
JP |
|
Oxford Square Capital Corp
NASDAQ:OXSQ
|
US |
|
PowerFleet Inc
NASDAQ:AIOT
|
US |
|
Huarong International Financial Holdings Ltd
HKEX:993
|
HK |
|
H
|
Hangzhou Advance Gearbox Group Co Ltd
SSE:601177
|
CN |
Helixmith Co Ltd
Stock-Based Compensation
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Helixmith Co Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Stock-Based Compensation
₩23B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
19%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Stock-Based Compensation
₩2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Stock-Based Compensation
₩1.2B
|
CAGR 3-Years
56%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Stock-Based Compensation
₩5.5B
|
CAGR 3-Years
25%
|
CAGR 5-Years
39%
|
CAGR 10-Years
24%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Stock-Based Compensation
₩5.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
Helixmith Co Ltd Intrinsic Value
LOCKED
